Efter markedsføring er et differentieringssyndrom, som retinoinsyresyndrom, også blevet rapporteret ved behandling af andre maligniteter end APL med TRISENOX.
In post marketing experience, a differentiation syndrome, like retinoic acid syndrome, has also been reported for the treatment of malignancies other than APL with TRISENOX.